Corning Incorporated subsidiary, Mediatech, Inc., and Biological Industries, Ltd. (BI) has announced an agreement to enable cell therapy research and manufacturing organizations to purchase the innovative, xeno-free human pluripotent stem-cell (hPSC) medium in conjunction with Corning’s other leading stem-cell culture products.
“This product augments our growing portfolio of media and reagents, and our technical team has shown excellent results using NutriStem hPSC Medium in combination with our advanced cell culture surfaces and vessels,” said Keith Olson director, business operations, Corning Life Sciences. “Corning continues to innovate across our portfolio, both through our internal development as well as through external relationships with exceptional technology developers.”
The jointly branded NutriStem® hPSC Medium will continue to be manufactured by BI, but supported by Corning’s global commercial team. This medium was developed by BI in collaboration with the Technion – Israel Institute of Technology. Since its release in 2009, the media have been increasingly adopted by leading academic and commercial labs for use in hPSC culture.
“Corning is a market leader in cell culture and brings broad access to life science customers globally,” said Alon Ariel, chief executive officer, BI. “It is critical for our products to have high availability for researchers’ workflows, now that stem cell research and development are accelerating into clinical trials and therapeutic use. Corning has both the complementary products and the commercial breadth to facilitate this.”
Corning Life Sciences continues to bring new and innovative laboratory technologies to researchers worldwide and helps customers succeed by providing novel, high-quality products and services in cell culture, bioprocessing, drug discovery and development, genomics, and microbiology.